IpiNovyx Bio Closes on $10 Million Seed Financing Round to Advance Proprietary Platform
“New York-based IpiNovyx Bio announced the closing of a $10 million seed financing round. The financing was led by Viva BioInnovator (a Viva Biotech division) and included participation from Lilly, Opaleye Management, Orange Grove Bio, and Alexandria Venture Investments. Ipinovyx is developing a platform of best-in-class immunoproteasome modulating therapeutics for the treatment of autoimmune and inflammatory diseases. Proceeds from the financing will support the company’s continued advancement of its lead drug candidates toward first-in-human clinical studies, including submission of the company’s first investigational new drug (IND) application. “Orange Grove Bio is dedicated to partnering with world-class researchers to advance the most promising drug development technologies emerging from leading academic institutions. We believe that IpiNovyx’s scientific founders and their unique approach to developing best-in-class immunoproteasome inhibitors are the ideal fit for this model,” said Marc Appel, co-founder, and chief executive officer of IpiNovyx and chief executive officer of Orange Grove Bio. “This seed funding will enable the company to rapidly …”
New York biotech firm moving HQ to Cincinnati The following excerpt was taken from Cincyinno Business Journal — continue reading here. A New York-based biotech firm is moving its corporate headquarters to the University of Cincinnati’s 1819 Innovation Hub “A New York-based biotech firm is moving its corporate headquarters to the University of Cincinnati’s 1819… Continue reading New York biotech firm moving HQ to Cincinnati
September 29, 2020
Our first portfolio company, Asalyxa Bio, has launched
Our first portfolio company, Asalyxa Bio, has launched. The University of Michigan, our partner in the creation of this company, released a press release which can be read below. — Asalyxa Bio, a startup with neutrophil targeting drug-delivery technology invented at University of Michigan Asalyxa Bio, a startup with neutrophil targeting drug-delivery technology invented at… Continue reading Our first portfolio company, Asalyxa Bio, has launched
February 9, 2022
1819 Innovation Hub tenant inks key partnership with Korea VC firm
1819 Innovation Hub tenant inks key partnership with Korea VC firm The following excerpt was taken from TechOhio– continue reading here. A biotech firm that moved its headquarters from New York to Cincinnati in late 2021 has announced its first major collaboration A biotech firm that moved its headquarters from New York to Cincinnati in… Continue reading 1819 Innovation Hub tenant inks key partnership with Korea VC firm
January 31, 2020
Michigan BioSocial
Michigan BioSocial Upcoming Webinar for Pre-Clinical Biotech Development Opportunities
March 9, 2021
Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio
Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio The following was taken from PR Newswire and you can read it here: https://www.prnewswire.com/news-releases/research-bridge-partners-seed-capital-investment-in-asalyxa-bio-advances-dr-lola-eniola-adefesos-immune-cell-targeted-therapeutic-platform-301242853.html “Research Bridge Partners – a 501 (c) (3) organization that bridges preeminent innovators at mid-continent research universities AUSTIN, Texas, March 9, 2021 /PRNewswire/ — Research Bridge Partners – a 501 (c) (3)… Continue reading Research Bridge Partners’ Seed Capital Investment in Asalyxa Bio
June 23, 2022
Orange Grove Bio Appoints Key Leadership & New Academic Collaboration
The University of Pittsburgh and Orange Grove Bio Establish Partnership… The following excerpt was taken from Globe Newswire — continue reading here. Orange Grove Bio, a preclinical drug investment and development firm, today announced several key leadership appointments highlighted by its naming John C. Byrd, M.D. Orange Grove Bio, a preclinical drug investment and development… Continue reading Orange Grove Bio Appoints Key Leadership & New Academic Collaboration
January 25, 2020
IF HENRY FORD WERE IN BIOTECH
IF HENRY FORD WERE IN BIOTECH Please join us to hear from our CEO, Marc Appel.
February 25, 2021
Wall Street Journal
Wall Street Journal The following was taken from the Wall Street Journal. Check out the original piece here: https://www.wsj.com/articles/vc-daily-biotechs-test-new-company-building-model-11614261635 We are incredibly excited and humbled to be recognized in the Wall Street Journal for our innovative business model! We thank everyone who has been supporting us from the beginning.
May 11, 2020
New Podcast Launched
We are ecstatic to announce that we have launched our new podcast “OGB Podcast” on both Spotify and Anchor. We will be talking to industry leaders about the state of the biotech industry as well as delving into the specifics of our guests expertise. You can find and listen to us on Spotify ( https://open.spotify.com/show/0tSRtB4tFUcqHhW43RkWIL… Continue reading New Podcast Launched